A new study suggests that some recently marketed migraine medications may not be more effective than standard painkillers for treating acute migraine episodes.  

The FDA approved Kisqali for patients with stage 2 or 3 breast cancer and who are at high risk of recurrence. 

On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen testified at a Senate committee hearing about the costs for Wegovy and Ozempic.

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18. 

Starting Oct. 1, a Louisiana law will classify drugs used for abortion — mifepristone and misoprostol — as controlled substances, requiring hospitals to store them in locked cabinets, The Washington Post reported Sept. 17. 

Johnson & Johnson has decided to terminate implementation of its 340B rebate plan, according to an internal email 340B Health shared with Becker's.

GLP-1 weight loss medications like Ozempic and Wegovy have become blockbuster drugs, but the need for weekly injections has limited their use. This may soon change, as several oral versions are nearing FDA approval, CNN reported Sept. 17.

Type 2 diabetes drug metformin could help reduce the viral reservoir — or clear it completely — in people living with HIV who are using antiretrovirals, according to a study published in September in the journal iScience. 

Once Ozempic's exclusivity ends, drug manufacturers could sell generic versions for less than $100 per month, Sen. Bernie Sanders said Sept. 17. Before insurance, the brand-name drug costs $969 per month in the U.S.

Sens. Dick Durbin and Mike Braun proposed a new bill, the Protecting Patients from Deceptive Drugs Online Act, in an effort to regulate online promotion of prescription drugs by telehealth firms and influencers.